

Notification concerning a single shareholder

ISSUER

Name of the Issuer

Evolva Holding SA

Part 1: PERSON SUBJECT TO REPORTING OBLIGATION

Information regarding the beneficial owner

Company name

Novartis AG

Family name / First name

Street

Lichtstrasse 35

ZIP / City

4056 Basel

Country

Switzerland

Part 2: IN CASE OF INDIRECT PURCHASE OR INDIRECT SALE

Details regarding the direct acquirer / seller i

Company name

Novartis BioVentures Ltd.

Family name / First name

Street

131 Front Street

ZIP / City

Hamilton HM12

Country

Bermuda

Relation between the direct acquirer / seller and the beneficial owner

Type of relation i

- Other
- Group of companies
- Nominee
- Trustee
- Investment company

Remarks

Part 3: FACTS AND CIRCUMSTANCES TRIGGERING THE OBLIGATION TO NOTIFY

Date of the purchase or sale

01.09.2011

Date of transfer of equity securities

01.09.2011

Date of the notification by the shareholder i

01.09.2011

Trigger for obligation to notify i

- Other
- Acquisition
- Sale
- Securities lending
- Capital increase
- Capital reduction
- Exercise of financial instruments
- Expiration of financial instruments
- Creation of a group
- Termination of a group
- Change in group composition

Remarks

Termination of Lock-up and Coordinated Sale Agreement dated 13 December 2010 and amended on 17 May 2011.

Details regarding the contact person

Company name

Family name / First name /

Street

P.O. Box

ZIP / City

Country

E-Mail

Phone / Fax /

Voting rights total

Voting rights < 3% (for purchase positions as well as for sale positions)

Part 4: DISCLOSURE OF PURCHASE POSITIONS

Percentage of voting rights (total of all purchase positions) %

1.) Equity securities: **Shares**

	Number of rights	Number of voting rights	Percentage of voting rights
1.1.) <input type="text" value="Registered share"/>	<input type="text" value="7'898'068"/>	<input type="text" value="7'898'068"/>	<input type="text" value="4.58"/> %

2.) Financial instruments: 

No information.

3.) Financial instruments which economically enable the purchase of equity securities in respect of a public tender offer: 

No information.

Part 5: DISCLOSURE OF SALE POSITIONS

Percentage of voting rights (total of all sale positions) %

Sale positions: 

No information.

Part 6: DETAILS REGARDING THE PUBLICATION

Status of publication

In preparation by issuer

Filed for preliminary check by the Disclosure Office

Approved for publication

Rejected by the Disclosure Office

Obsolete due to amendment or erasure

Discarded draft

Remarks regarding the publication

Details regarding the notification submission

Date / Time	<input type="text" value="05.09.2011"/>	<input type="text" value="21:12:34"/>
Company name	<input type="text" value="Evolva Holding SA"/>	
Family name / First name	<input type="text" value="Verbraeken"/>	<input type="text" value="Paul"/>
E-Mail	<input type="text" value="paul.verbraeken@arpida.com"/>	
Phone / Fax	<input type="text" value="061 485 2035"/>	<input type="text"/>
Data entry	<input checked="" type="radio"/> Regular publication by issuer	
	<input type="radio"/> Extraordinary publication by Disclosure Office	
Approval	<input checked="" type="radio"/> After preliminary check by the Disclosure Office	
	<input type="radio"/> Directly by the issuer	
Specifications regarding the publication		
Date / Time	<input type="text" value="06.09.2011"/>	<input type="text" value="09:43:38"/>
Checked by	<input type="text" value="severine.wegmueller@six-group.com/six"/>	
Remarks of the Disclosure Office	<input type="text"/>	

[close](#)